Sonya Reid — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications4liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CapecitabineThis is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.	Cancer, Parkinson	Phase 2	À vérifier	United States	À vérifier
CapecitabineThis is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.	Cancer	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Capecitabine	Cancer	Phase 2	NCT05693766	INSIGHT — Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort	RECRUITING

Publications

4

Molécule	Indication / population	Titre	Journal	Date
Capecitabine		Research on the impact of different chemotherapy and targeted therapy regimens on postoperative disease-free survival in breast cancer patients.	Pakistan journal of pharmaceutical sciences
Capecitabine		Locoregional recurrence of triple-negative breast cancer with low tumor-infiltrating lymphocytes: a case report.	The Pan African medical journal
Capecitabine		Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.	Breast cancer research and treatment
Capecitabine		Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal.	Cancers